| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurosciences (Drs. Masliah, Hansen, Adame, and Crews) and Pathology (Drs. Masliah and Hansen), University of California San Diego, La Jolla; Elan Pharmaceuticals Inc. (Drs. Bard, Lee, Seubert, Games, and Schenk), South San Francisco, CA; and Pivotol Research Centers (Dr. Kirby), Peoria, AZ.
Address correspondence and reprint requests to Dr. Eliezer Masliah, Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093-0624; e-mail: emasliah{at}UCSD.edu
The authors report a patient with Alzheimer disease (AD) without encephalitis who was immunized with AN-1792 (an adjuvanted formulation of Aß-42). There were no amyloid plaques in the frontal cortex and abundant Aß-immunoreactive macrophages, but tangles and amyloid angiopathy were present. The white matter appeared normal and minimal lymphocytic infiltration in the leptomeninges was observed. This case illustrates the effects of an Aß-based immunization on AD pathogenesis in the absence of overt meningoencephalitis and leukoencephalopathy.
Received February 10, 2004. Accepted in final form June 17, 2004.
Related Articles
Neurology 2005 64: 10-12.
Neurology 2005 64: 94-101.
This article has been cited by other articles:
|
|
 |
|
  S. SALLOWAY and S. CORREIA Alzheimer disease: Time to improve its diagnosis and treatment Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Boche, E. Zotova, R. O. Weller, S. Love, J. W. Neal, R. M. Pickering, D. Wilkinson, C. Holmes, and J. A. R. Nicoll Consequence of A{beta} immunization on the vasculature of human Alzheimer's disease brain Brain, December 1, 2008; 131(12): 3299 - 3310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schroeter, K. Khan, R. Barbour, M. Doan, M. Chen, T. Guido, D. Gill, G. Basi, D. Schenk, P. Seubert, et al. Immunotherapy Reduces Vascular Amyloid-{beta} in PDAPP Mice J. Neurosci., July 2, 2008; 28(27): 6787 - 6793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Head, V. Pop, V. Vasilevko, M. Hill, T. Saing, F. Sarsoza, M. Nistor, L.-A. Christie, S. Milton, C. Glabe, et al. A Two-Year Study with Fibrillar {beta}-Amyloid (A{beta}) Immunization in Aged Canines: Effects on Cognitive Function and Brain A{beta} J. Neurosci., April 2, 2008; 28(14): 3555 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hoyer, C. Gronwall, A. Jonsson, S. Stahl, and T. Hard Stabilization of a {beta}-hairpin in monomeric Alzheimer's amyloid-{beta} peptide inhibits amyloid formation PNAS, April 1, 2008; 105(13): 5099 - 5104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Vasilevko, F. Xu, M. L. Previti, W. E. Van Nostrand, and D. H. Cribbs Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid- in CNS of Tg-SwDI Transgenic Mice J. Neurosci., December 5, 2007; 27(49): 13376 - 13383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Petrushina, A. Ghochikyan, M. Mktrichyan, G. Mamikonyan, N. Movsesyan, H. Davtyan, A. Patel, E. Head, D. H. Cribbs, and M. G. Agadjanyan Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice J. Neurosci., November 14, 2007; 27(46): 12721 - 12731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements J. Neurosci., August 22, 2007; 27(34): 9115 - 9129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, N. Movsesyan, E. Mina, A. Kiyatkin, C. G. Glabe, D. H. Cribbs, et al. Anti-Abeta1 11 Antibody Binds to Different beta-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers J. Biol. Chem., August 3, 2007; 282(31): 22376 - 22386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tampellini, J. Magrane, R. H. Takahashi, F. Li, M. T. Lin, C. G. Almeida, and G. K. Gouras Internalized Antibodies to the Abeta Domain of APP Reduce Neuronal Abeta and Protect against Synaptic Alterations J. Biol. Chem., June 29, 2007; 282(26): 18895 - 18906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Klunk, J. C. Price, C. A. Mathis, N. D. Tsopelas, B. J. Lopresti, S. K. Ziolko, W. Bi, J. A. Hoge, A. D. Cohen, M. D. Ikonomovic, et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees J. Neurosci., June 6, 2007; 27(23): 6174 - 6184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bombois, C.-A. Maurage, M. Gompel, V. Deramecourt, M.-A. Mackowiak-Cordoliani, R. S. Black, R. Lavielle, A. Delacourte, and F. Pasquier Absence of beta-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia Arch Neurol, April 1, 2007; 64(4): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oddo, V. Vasilevko, A. Caccamo, M. Kitazawa, D. H. Cribbs, and F. M. LaFerla Reduction of Soluble Abeta and Tau, but Not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles J. Biol. Chem., December 22, 2006; 281(51): 39413 - 39423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Levites, L. A. Smithson, R. W. Price, R. S. Dakin, B. Yuan, M. R. Sierks, J. Kim, E. McGowan, D. K. Reed, T. L. Rosenberry, et al. Insights into the mechanisms of action of anti-A{beta} antibodies in Alzheimer's disease mouse models FASEB J, December 1, 2006; 20(14): 2576 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Levites, K. Jansen, L. A. Smithson, R. Dakin, V. M. Holloway, P. Das, and T. E. Golde Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid beta, Amyloid beta40, and Amyloid beta42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice. J. Neurosci., November 15, 2006; 26(46): 11923 - 11928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Buckwalter, B. S. Coleman, M. Buttini, R. Barbour, D. Schenk, D. Games, P. Seubert, and T. Wyss-Coray Increased T Cell Recruitment to the CNS after Amyloid beta1-42 Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-beta1. J. Neurosci., November 1, 2006; 26(44): 11437 - 11441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain, November 1, 2006; 129(11): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Patton, W. M. Kalback, C. L. Esh, T. A. Kokjohn, G. D. Van Vickle, D. C. Luehrs, Y.-M. Kuo, J. Lopez, D. Brune, I. Ferrer, et al. Amyloid-{beta} Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients: A Biochemical Analysis Am. J. Pathol., September 1, 2006; 169(3): 1048 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Rosenberg Time Will Be of the Essence in Treating Alzheimer Disease JAMA, July 19, 2006; 296(3): 327 - 329. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Rosenberg Treating Alzheimer disease: time matters. Arch Neurol, July 1, 2006; 63(7): 926 - 928. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wilcock, J. Alamed, P. E. Gottschall, J. Grimm, A. Rosenthal, J. Pons, V. Ronan, K. Symmonds, M. N. Gordon, and D. Morgan Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci., May 17, 2006; 26(20): 5340 - 5346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maier, T. J. Seabrook, N. D. Lazo, L. Jiang, P. Das, C. Janus, and C. A. Lemere Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci., May 3, 2006; 26(18): 4717 - 4728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Rosenberg Translational Research on the Way to Effective Therapy for Alzheimer Disease Arch Gen Psychiatry, November 1, 2005; 62(11): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gilman, M. Koller, R. S. Black, L. Jenkins, S. G. Griffith, N. C. Fox, L. Eisner, L. Kirby, M. B. Rovira, F. Forette, et al. Clinical effects of A{beta} immunization (AN1792) in patients with AD in an interrupted trial Neurology, May 10, 2005; 64(9): 1553 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Fox, R. S. Black, S. Gilman, M. N. Rossor, S. G. Griffith, L. Jenkins, M. Koller, and for the AN1792(QS-21)-201 Study Team Effects of A{beta} immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology, May 10, 2005; 64(9): 1563 - 1572. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
